Abstract:The gastrointestinal stromal tumor(GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract,and was different from leiomyoma,neurogenic tumor,which occurs mainly with the Kit gene and platelet-derived growth factor receptor alpha gene mutation.Targeting KIT has led to a new treatment paradigm in GISTs.Imatinib and sunitinib,both tyrosine kinase inhibitors directed to KIT,were approved for first-and second-line treatment of metastatic and unresectable GISTs.In this article,we will review the molecular classification and targeted drug therapy of GISTs.

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors